	US 12,239,712 B2
	Combination therapy for the treatment of liver disease
Allen Baharaff, Tel Aviv (IL); Liat Hayardany-Nissimov, Tel Aviv (IL); and Tali Gorfine, Tel Aviv (IL)
Assigned to GALMED RESEARCH AND DEVELOPMENT LTD, Tel Aviv (IL)
Appl. No. 17/273,318
Filed by GALMED RESEARCH AND DEVELOPMENT LTD, Tel Aviv (IL)
PCT Filed Sep. 3, 2019, PCT No. PCT/IL2019/050983 § 371(c)(1), (2) Date Mar. 4, 2021, PCT Pub. No. WO2020/049556, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/727,565, filed on Sep. 6, 2018.
Prior Publication US 2021/0338826 A1, Nov. 4, 2021
Int. Cl. A61K 31/192 (2006.01); A61K 31/53 (2006.01); A61K 31/575 (2006.01); A61K 31/665 (2006.01); A61K 47/54 (2017.01); A61P 1/16 (2006.01)

CPC A61K 47/554 (2017.08) [A61K 31/192 (2013.01); A61K 31/53 (2013.01); A61K 31/575 (2013.01); A61K 31/665 (2013.01); A61P 1/16 (2018.01)]

16 Claims

1. A therapeutic combination comprising a therapeutically effective amount of aramchol, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of MGL-3196, or a pharmaceutically acceptable salt thereof, and a carrier.